Value Partners Investments Inc. lessened its holdings in shares of CVS Health Co. (NYSE: CVS – Get Rating) by 2.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 719,199 shares of the pharmacy operator’s stock after selling 15,763 shares during the quarter. CVS Health makes up 6.2% of Value Partners Investments Inc.’s portfolio, making its stock its 3rd largest holding. Value Partners Investments Inc. owned 0.05% of CVS Health worth $ 72,763,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Griffin Asset Management Inc. increased its stake in CVS Health by 0.5% during the 4th quarter. Griffin Asset Management Inc. now owns 21,187 shares of the pharmacy operator’s stock valued at $ 2,186,000 after purchasing an additional 95 shares in the last quarter. Townsend Asset Management Corp NC ADV increased its stake in CVS Health by 0.6% during the 4th quarter. Townsend Asset Management Corp NC ADV now owns 17,344 shares of the pharmacy operator’s stock valued at $ 1,789,000 after purchasing an additional 96 shares in the last quarter. Garrett Investment Advisors LLC increased its stake in CVS Health by 1.5% during the 4th quarter. Garrett Investment Advisors LLC now owns 6,831 shares of the pharmacy operator’s stock valued at $ 705,000 after purchasing an additional 98 shares in the last quarter. First Bancorp Inc ME increased its stake in CVS Health by 2.8% during the 4th quarter. First Bancorp Inc ME now owns 3,590 shares of the pharmacy operator’s stock valued at $ 371,000 after purchasing an additional 98 shares in the last quarter. Finally, Gryphon Financial Partners LLC increased its stake in CVS Health by 2.0% during the 4th quarter. Gryphon Financial Partners LLC now owns 5,084 shares of the pharmacy operator’s stock valued at $ 525,000 after purchasing an additional 99 shares in the last quarter. Institutional investors own 78.00% of the company stock.
In related news, EVP Daniel P. Finke sold 55,359 shares of the firm’s stock in a transaction dated Monday, April 4th. The shares were sold at an average price of $ 100.13, for a total transaction of $ 5,543,096.67. Following the completion of the sale, the executive vice president now directly owns 3,098 shares in the company, valued at $ 310,202.74. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Prem S. Shah sold 5,346 shares of the firm’s stock in a transaction dated Wednesday, March 30th. The stock was sold at an average price of $ 104.70, for a total transaction of $ 559,726.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 77,659 shares of company stock valued at $ 7,882,993. 0.69% of the stock is owned by company insiders.
CVS has been the topic of a number of recent analyst reports. Tigress Financial upped their price target on shares of CVS Health from $ 122.00 to $ 125.00 in a research note on Thursday, April 7th. Sanford C. Bernstein downgraded shares of CVS Health from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $ 122.00 to $ 112.00 in a report on Thursday, May 26th. Deutsche Bank Aktiengesellschaft increased their price target on shares of CVS Health from $ 110.00 to $ 113.00 in a report on Thursday, May 5th. Loop Capital began coverage on shares of CVS Health in a report on Thursday, June 16th. They set a “buy” rating and a $ 120.00 price target on the stock. Finally, StockNews.com initiated coverage on shares of CVS Health in a report on Thursday, March 31st. They set a “strong-buy” rating on the stock. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $ 116.05.
Shares of NYSE CVS opened at $ 92.37 on Friday. The firm has a 50-day simple moving average of $ 96.85 and a 200-day simple moving average of $ 101.42. The stock has a market capitalization of $ 121.13 billion, a price-to-earnings ratio of 15.34, a price-to-earnings-growth ratio of 1.44 and a beta of 0.78. The company has a quick ratio of 0.62, a current ratio of 0.88 and a debt-to-equity ratio of 0.70. CVS Health Co. has a 52 week low of $ 79.33 and a 52 week high of $ 111.25.
CVS Health (NYSE: CVS – Get Rating) last issued its earnings results on Wednesday, May 4th. The pharmacy operator reported $ 2.22 EPS for the quarter, beating analysts’ consensus estimates of $ 2.14 by $ 0.08. The business had revenue of $ 76.83 billion during the quarter, compared to analysts’ expectations of $ 75.30 billion. CVS Health had a net margin of 2.67% and a return on equity of 15.33%. The company quarterly revenue was up 11.2% compared to the same quarter last year. During the same period in the prior year, the business earned $ 2.04 earnings per share. As a group, equities research analysts expect that CVS Health Co. will post 8.34 EPS for the current year.
CVS Health Profile: (Get Rating)
CVS Health Corporation provides health services in the United States. The company Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, government units, government-sponsored plans, labor groups, and expatriates.
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE: CVS – Get Rating).
Receive News & Ratings for CVS Health Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CVS Health and related companies with MarketBeat.com’s FREE daily email newsletter.